Altimmune vs Ibio
Ibio is the larger business, with $100,000 of revenue in fiscal 2026 against $41,000 for Altimmune (2.4 times as much). Altimmune grew faster (105.0% against -75.0%). Ibio kept more of each dollar of sales as profit: a net margin of -33044.0% against -214861.0%.
| Latest fiscal year | AltimmuneALT, 2025 | IbioIBIO, 2026 |
|---|---|---|
| Revenue | $41,000 | $100,000 |
| Revenue growth | 105.0% | -75.0% |
| Net income | −$88.1m | −$33.0m |
| Operating margin | — | -35141.0% |
| Net margin | -214861.0% | -33044.0% |
| Return on equity | -50.6% | -65.7% |
| Free cash flow | −$67.5m | −$23.8m |
| Cash | $43.8m | $56.4m |
| Total debt | $35.0m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 57 | 23 |
| Market value | $398m | $45.5m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 11 buys, 0 sales | 4 buys, 0 sales |